

Accompanying Documents

1. Marked-up copies of the claims incorporating the amendments made herein (Appendix A).
2. Clean copies of the pending claims after incorporation of the amendments made herein (Appendix B).

AMENDMENT

In the Claims:

Please cancel claim 15, without prejudice or disclaimer.

Attached hereto is a marked-up version of the changes made to the specification and claims by the current amendment. The attached pages are captioned **“Version with markings to show changes made.”**

APPENDIX B
Currently Pending Claims

1. An immunogenic composition comprising NmC oligosaccharide conjugated to a first carrier and NmB outer membrane protein.
2. The immunogenic composition of claim 1 wherein said first carrier is selected from the group consisting of protein, polysaccharide, polylactic acid, polyglycolic acid, polymeric amino acids, amino acid co-polymer, lipid aggregate, and inactive virus particle.
3. The immunogenic composition of claim 2 wherein said first carrier is a protein.
4. The immunogenic composition of claim 3 wherein said first carrier is CRM₁₉₇.
5. The immunogenic composition of claim 1 the NmB outer membrane protein is presented as proteoliposomic vesicles.
6. The immunogenic composition of claim 1 wherein said composition comprises a second carrier.
7. The immunogenic composition of claim 6 wherein said second carrier is aluminum hydroxide or MF59.
8. A method of inducing an immunologic response to NmB and NmC comprising administering an immunologically effective amount of an immunogenic composition of claim 1.

9. The method of claim 8 wherein said first carrier is selected from the group consisting of protein, polysaccharide, polylactic acid, polyglycolic acid, polymeric amino acids, amino acid co-polymer, lipid aggregate, and inactive virus particle.
10. The method of claim 9 wherein said first carrier is a protein.
11. The method of claim 10 wherein said first carrier is CRM₁₉₇.
12. The method of claim 8 the NmB outer membrane protein is presented as proteoliposomic vesicles.
13. The method of claim 8 wherein said composition comprises a second carrier.
14. The method of claim 13 wherein said second carrier is aluminum hydroxide or MF59.
16. (Twice amended) A method of vaccinating an individual comprising administering to said individual an immunogenic composition of any one of claims 8-14.